Case report: The effect of induction targeted therapies in stage III driver mutants non-small cell lung cancer
This case series highlights the potential of targeted therapies for resectable NSCLC in the neoadjuvant setting. Further research is required to confirm their benefits, assess their safety and efficacy, and determine optimal timing and sequencing.
Authors
- Laila C. Roisman (ORCID: https://orcid.org/0000-0001-8455-9327)
- Bilal Krayim
- Nir Peled (ORCID: https://orcid.org/0000-0003-3714-4377)
- Adi Idris (ORCID: https://orcid.org/0000-0002-0562-1549)
- Daniel Fink (ORCID: https://orcid.org/0000-0003-3548-6736)
- Betsy Giles
- Waleed Kian (ORCID: https://orcid.org/0000-0003-4956-9364)
- Nasim A. Elkiaan
Institutions
- Ben-Gurion University of the Negev (IL)
- Shaare Zedek Medical Center (IL)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-11-13
- DOI
- https://doi.org/10.3389/fonc.2024.1286116
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.84